Singapore markets open in 8 hours 17 minutes
Straits Times Index
3,303.66 +12.96 (+0.39%) S&P 500
5,224.71 +2.03 (+0.04%) Dow
39,494.00 -18.84 (-0.05%) Nasdaq
16,395.30 +54.43 (+0.33%) Bitcoin USD
63,254.59 +1,583.45 (+2.57%) CMC Crypto 200
1,303.69 +43.48 (+3.45%)
Revance Therapeutics, Inc. (RVNC)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 12:43PM EDT. Market open.
| Previous close | 3.3200 |
| Open | 3.4000 |
| Bid | 3.2500 x 800 |
| Ask | 3.2900 x 300 |
| Day's range | 3.2250 - 3.6000 |
| 52-week range | 3.0000 - 35.4550 |
| Volume | |
| Avg. volume | 1,944,067 |
| Market cap | 342.07M |
| Beta (5Y monthly) | 1.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2024 Earnings Call Transcript
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q1 2024 Earnings Call Transcript May 9, 2024 Revance Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Revance Therapeutics First Quarter2024 Financial Results and Corporate Update Conference Call. At this time, […]
- GuruFocus.com
Revance Therapeutics Reports Q1 2024 Financial Results: Revenue Growth Amidst Rising Operating ...
Despite Increased Revenues, Revance Faces Higher Operating Costs and a Persistent Net Loss
- Zacks
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue Estimates
Revance Therapeutics (RVNC) delivered earnings and revenue surprises of 18.18% and 6.66%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
© 2024 Yahoo. All rights reserved.